Secondary Logo

Journal Logo

Review Articles

Light therapy: a new option for neurodegenerative diseases

Liu, Yu-Lu1; Gong, Si-Yi1; Xia, Shu-Ting2; Wang, Ya-Li3; Peng, Hao4; Shen, Yun1; Liu, Chun-Feng2,5

Editor(s): Yin, Yan-JieHao, Xiu-Yuan

Author Information
doi: 10.1097/CM9.0000000000001301
  • Open

Abstract

Introduction

Neurodegenerative diseases (NDs) are a broad, highly heterogeneous group of disorders affecting both the central nervous system (CNS) and the peripheral nervous system and are characterized by irreversible, progressive loss of previously intact neurological function, worsening with age.[1] It includes Alzheimer disease (AD), Parkinson disease (PD), Huntington disease (HD), motor neuron disease, and others. The pathogenesis of ND is still unclear and may vary across specific diseases. Despite significant global morbidity and mortality, there are no curative treatments for ND. ND reduces the quality of life of patients and their families. At present, the mainstay treatments of ND are pharmaceutics, but the available drugs provide only symptomatic relief and usually carry the risk of adverse reactions, such as diarrhea, nausea, headache, and others. In contrast, physical therapies and chronotherapies, such as transcranial magnetic stimulation (TMS), light therapy (LT), and physical exercise (like Tai Chi), have attracted the attention of researchers due to their high safety, low cost, and feasibility of implementation.[2–7]

The LT, sometimes referred to as heliotherapy, consists of controlled exposure to either daylight or a comparable source of artificial light, and has been reported to be an economic, convenient, safe, and effective way to ease symptoms of sleep disorders, depression, and cognitive disorders.[8–10] There have been some researches investigating the effectiveness of light in the treatment of ND.[10–13] In this article, we review the current evidence on the mechanism, therapeutic methods, and efficacy of LT in ND.

Mechanisms of LT

The circadian rhythm refers to behavioral and biological cycles that are regulated by an endogenous system. This biological cycle repeats roughly every 24 h, even in the absence of environmental influence. Although circadian rhythms persist in the absence of external cues, many extrinsic stimuli can entrain the intrinsic time-keeping system to maintain synchrony with the earth's light-dark cycle. Environmental stimuli signaling the progression of time are known as zeitgeber, a German word meaning “time giver,” and include light as the most prominent signal, as well as others, such as patterns of exercise,[14] food consumption,[15] social activity, and more.

Clock gene

The master circadian clock in human beings is localized in the hypothalamus over the optic chiasm and is thus named the suprachiasmatic nucleus (SCN) [Figure 1]. The clock gene plays an important role in the circadian regulation mechanism. Clock genes include Per1, Per2, CRY1, CRY2, Bmal1/Clock, and others. In addition, some studies have found that clock genes are related to the pathological mechanisms of metabolic diseases, tumors, and other diseases, suggesting that clock genes may be important not only for regulating the circadian rhythm but also for driving the occurrence or progression of certain diseases. In general, light, activity, and food intake send signals to the SCN as important feedback for the circadian timing system. The clock genes form the molecular machinery of this circadian system, operating via autoregulatory feedback loops. However, of interest, prior studies have found that there is a complex relationship between the circadian rhythm and the clinical symptoms of ND.[16]

Figure 1
Figure 1:
Schematic representation of the mechanism underlying LT. In general, light exerts its function through visual and non-visual perception pathways. As the circadian master, SCN regulates clock gene oscillations, thus synchronizing multiple central and peripheral structures. LT: Light therapy; SCN: Suprachiasmatic nucleus; ipRGCs: Intrinsically photosensitive retinal ganglion cells; AP-1: Activator protein-1; ROS: Reactive oxygen species; NF-κB: Nuclear factor-κB.

Melatonin (MT)

MT, a hormone that regulates the circadian rhythm and promotes sleep, is mainly secreted by the pineal gland. The secretion of MT is regulated by the SCN and follows the patterns of the circadian rhythm. Specifically, secretion increases at night and decreases during the day. The SCN interacts with the pineal gland to influence this cycle of production. After light stimulation during the day, the SCN acts on the pineal gland to suppress the secretion of MT, leading to a low concentration of MT in the blood and thus reducing drowsiness. In contrast, in the absence of light at night, the SCN no longer inhibits the pineal gland, leading to increased production of MT which reaches a peak in the early morning and then decreases slowly, promoting wakefulness.[17] Through this pathway, MT converts the neural information initiated after the perception of light into biochemical information through the SCN's action on the pineal gland, ultimately affecting the human body's rhythm.[18] In ND, changes in the secretion of MT can cause disorders in the circadian rhythm of the human body.

Other physiological impacts of light

However, of interest, light appears to stimulate biochemical responses without a strict requirement for visual perception. Recent evidence from animal experiments has suggested that illumination of the trunk (and not the head or eyes) still affords neuroprotective effects.[19–21] Though the concrete mechanisms underlying this effect, called remote photobiomodulation (PBM), are not entirely clear, it is likely that light activates one or more molecules or cells in the body, such as immune cells, inflammatory mediators, or bone marrow-derived stem cells. These cells presumably rescue neuronal functions by releasing nerve growth factors or brain-derived neurotrophic factors. Different lights have different wavelengths that are absorbed, reflected, or scattered by various cellular organelles or tissues. In the body, the number of chromophores drives circadian photoentrainment after stimulation with a wide range of light wavelengths. However, each specific chromophore responds to a certain range of wavelengths. For example, for red and near-infrared (NIr) light, cytochrome c oxidase (CCO), the last enzyme in the respiratory chain, is the main photoreceptor and serves a vital role in the mechanism of PBM. CCO is composed of 13 protein subunits, including two heme centers and two copper centers. The absorption peaks of them appear to be different in the reduced and oxidized forms, mainly distributed in the range of the red spectrum (620–760 nm) and NIr spectrum (780–825 nm).[22–24] When the source emits the light ray, metal molecules in the CCO absorb photons and are stimulated from the ground state into upper, excited states.[25] During this process, nitric oxide (NO) photodissociates from CCO. In fact, NO typically inhibits electron transportation. Therefore, the mitochondrial membrane potential is increased after NO dissociation. Then, oxygen consumption levels are elevated and a proton gradient is established, ultimately resulting in a boost in ATP production.[26] These steps are followed by the production of reactive oxygen species, Ca2+, and cyclic adenosine monophosphate.[27] As second messengers, they could further activate a battery of signaling pathways and transcription factors.

Another hypothesis is the presence of a special signaling system between mitochondria across different organ systems. According to this theory, mitochondria under stress release an as-of-yet unidentified signaling molecule called mitokine, which consequently triggers a mitochondrial stress response in other areas of the body.[28] Of interest, light with wavelengths longer than the NIr spectrum, such as 980 nm,[29] 1064 nm,[30] and 1072 nm,[31] appear to be capable of exerting effects on biological tissues or cells, which strongly suggests the existence of other chromophores beyond CCO. Although no such evidence exists to date, it is possible that water molecules in light/heat sensitive channel play a role in mediating these effects. Although the results of prior experiments on PBM appear promising, many details supporting the theory require substantially more evidence, and further studies are needed to determine the mechanisms that are involved [Figure 1].

Application of Light in ND

AD

The AD is a degenerative disease of the CNS characterized by progressive cognitive and behavioral impairments and occurs in the elderly and pre-senile. Clinical symptoms include dysmnesia, aphasia, agnosia, impairment of visuospatial ability, abstraction, computational power, and changes in personality and behavior.[32] At present, there is no cure. The therapeutics used for the treatment only alleviate the symptoms of AD, and sometimes present side effects which may actually aggravate the patients’ condition.[32] Studies have shown that there is a bidirectional relationship between sleep and AD, in which sleep disturbance is associated with increased expression of biomarkers of AD. Sunset syndrome describes a set of emotional and cognitive changes sometimes seen in patients with AD and occurs when the light begins to fade (eg, at dusk), including emotional disorders, anxiety, hyperactivity, and a loss of sense of direction, lasting for several hours or the whole night. However, of interest, recent data have suggested that LT may play a role in addressing some of these effects by restoring the circadian rhythm, cognitive capacity, and emotional control.[33]

Animal models

A growing body of evidence has shown that intervention with NIr light ameliorates the negative cognitive effects of AD in mouse models, restoring memory capacity and leading to a reduction in amyloid-β (Aβ) burden in the brain. Several key findings have been summarized in Table 1.

Table 1 - Effect of light on animal models of Alzheimer disease.
First author, year, reference Subject Models PBM parameters Results/effects
Luis De Taboada, 2011[34] C57BL/6 mice Aβ protein precursor transgenic mice Transcranial, 2 min, 3 times/week, 6 months, 808 ± 10 nm, 10 mw/cm2 Dose-dependent reduction in amyloid load
Behavioral abnormalities ↓
SaβPPα↑ CTFβ↓
Julio C. Rojas, 2012[35] Adult male rats obtained from Harlan Fear conditioning Transcranial PBM, 660 nm, LLLT 1 J/cm2 (1 min 51 s) or LLLT 5 J/cm2 (9 min 25 s), 9 mw/cm2 Cortical metabolic capacity↑
Retention of extinction memories
Chengbo Meng, 2013[36] C57BL/6 mice APP/PS1 transgenic mice Illuminate at cells, 632.8 nm, 10 mw, 12.74 mw/cm2 Rescue dendrite atrophy
BDNF upregulation by activation of ERK/CREB pathway
Sivaraman Purushothuman, 2014[37] C57BL/6 mice K369I tau transgenic mice (K3)APP/PS1 transgenic mice Transcranial PBM, 670 nm, 90 s, 5 days/week for 4 weeks, 4 J/cm2 K3: hyperphosphorylated tau, neurofibrillary tangles, oxidative stress markers (4-hydroxynonenal and 8-hydroxy-2’-dexyguanosine) ↓, CCO↑ (in neocortex and hippocampus)
APP/PS1: size and number of Aβ plaques ↓
Dorit Farfara, 2014[38] C57/B6 male mice 5XFAD transgenic male mice (Tg6799) LLLT, implanted in skin on tibia, start at 4 months of age, weekly for 2 months, 1 J/cm2 Cognitive capacity and spatial learning ↑
Aβ in brain ↓
Proliferation of mesenchymal stem cells (mscs) ↑
Sivaraman Purushothuman, 2015[39] C57BL/6 mice APP/PS1 transgenic miceK3 transgenic mice Transcranial PBM, 670 nm, 90 s, 5 days/week for 4 weeks, 2 mw/cm2, 4 J/cm2 K3 mice: hyperphosphorylated tau, neurofibrillary tangles, oxidative stress↓, CCO↑ in cerebellum
APP/PS1 mice: Aβ deposition in cerebellar cortex ↓
Yujiao Lu, 2016[100] Male Sprague Dawley rats Aβ1–42 peptide injection Transcranial PBM, 2 mins daily for 5 consecutive days for 4 weeks, 808 nm, continuous wave, 8.33 ± 0.27 mw/cm2, 15 J/cm2 Aβ-induced hippocampal neurodegeneration ↓
Long-term spatial and recognition memory impairments ↓
Gwang Moo Cho, 2018[40] B6SJLF1. J mice 5XFAD mice Transcranial PBM, 610 nm, 1.7 mw/cm2, 2.0 J/cm2, 20 min, 3 times/week for 14 weeks. Amyloid accumulation, neuronal loss, and microgliosis↓
Cognitive function↑
Insulin degrading enzyme (IDE) ↑
Guillaume Blivet, 2018[41] Male Swiss mice Amyloid β 25–35 peptide-induced toxicity Rgn500, laser (850 nm), LED (850 nm, 625 nm), on top of the head or center of abdomen,10 mins daily for 7 days, 28 mw/cm2, 8.4 J/cm2. Memory restoration, normalization of amyloid β 1–42, ptau, oxidative stress, apoptosis (Bax/Bcl2), neuroinflammation.
Ekaterina Zinchenko, 2019 [42] Mongrel male mice Injection of amyloid β (1–42) peptide (1 μL, 200 μmol) Transcranial PBM, 1267 nm, 32 J/cm2, 9 days each second day Cognitive, memory and neurological status↑
Clearance of Aβ via the lymphatic system
Min Wang, 2019[43] APP/PS1 transgenic mice Mid-infrared light (2.5–4.0 μm) with peak wavelength 7.7–10 μm, 6weeks Learning and memory↑
Aβ in brain ↓
Gut microbiota compositions return to normal
Xiangpei Yue, 2019[44] C57BL/6 mice APP/PS1 transgenic mice Illuminate at skull and abdomen, 630 nm, 40 mins daily, 5 days/week for 2 consecutive months, 0.55 mw/cm2 Destroy Aβ assembly in vitro and in vivo
Activate FA dehydrogenase, facilitated Aβ aggregation
Smash Aβ deposition in ECS, recover ISF flow, rescue cognitive function
Aβ: Amyloid-β; LLLT: Low level light therapy; PBM: Photobiomodulation; CCO: Cytochrome C oxidase; LED: Light-emitting diode; ECS: Extracellular space; ISF: Intersitial fluid; BDNF: Brain-derived neurotrophic factor; ERK/ CREB: Extracellular signal-regulated kinases/cyclic AMP response element binding protein.

In 2011, Luis De Taboada carried the first experiment reporting the beneficial effects of PBM in AD animal models. By applying transcranial photobiomodulation (tPBM), amyloid-β protein precursor (AβPP) transgenic mice were examined and their behavioral abnormalities were alleviated with soluble AβPP increased and inflammatory markers decreased. In addition, a reduction of Aβ plaques was detected in a dose-dependent manner associated with NIr treatment.[34] Meng and colleagues discovered that low-level light therapy (LLLT) in APP/PS1 mice up-regulated brain-derived neurotrophic factor to reverse dendrite atrophy, during which ERK/CREB pathway would be activated as well.[36] Later, Sivaraman Purushothuman demonstrated the neuroprotective effects of NIr treatment in two mouse strains, K3 and amyloid precursor protein/presenilin 1 (APP/PS1) transgenic mice. Specifically, neurofibrillary tangles, hyperphosphorylated tau proteins, and oxidative stress markers decreased while cytochrome oxidase increased in the hippocampus and neocortex of K3 transgenic mice. In APP/PS1 mice, the number of Aβ declined and the size of the protein shrunk after NIr intervention.[37] The research team kept on evaluating whether NIr treatment had the protective effects for cerebellum in two mouse strains and the results proved the capability of NIr to ameliorate the neurodegeneration in cerebellum and possibly in any part of the brain.[39] In 2014, Farfara and her colleagues[38] creatively applied the LLLT to the bone marrow in 5XFAD transgenic mice model, placing the distal fiber on the middle part of the tibia, and the results showed an improvement of spatial learning with Aβ load decreased in brain and proliferation of mesenchymal stem cells increased. Another study employing 5XFAD mice but in a different animal background showed similar results. In detail, tPBM leads to the reduction in neuronal loss, microgliosis, Aβ accumulation, and improvement in cognitive function in 5XFAD mice. In 2019, Russian scientists first discovered that it is via the lymphatic system of the neck and the brain that tPBM removed Aβ to improve the cognitive, memory functions in Mongrel male mice.[42] In fact, NIr light treatment can accelerate Aβ degradation in extracellular space, therefore, recovering the interstitial fluid flow and reversing the cognitive function in APP/PS1 transgenic mice.[44] Intriguingly as well, Min Wang[43] reported the normalization of gut microbiota compositions in APP/PS1 transgenic mice after the application of Mid-infrared light (2.5–4.0 μm) for about 6 weeks.

In conclusion, tPBM effectively rescues the cognitive and memory functions in AD animal models primarily through the removal of Aβ proteins in the brain.

Patients

Sleep disorders

Sleep disorders in AD patients become increasingly serious with the progression and aggravation of the disease. Previous studies have confirmed the bidirectional relationship between AD and sleep disorders.[45] Light is often used to treat AD patients in clinical trials. Although different in several ways, LT has been suggested to be effective in improving sleep disorders in patients with AD, improving sleep quality, prolonging sleep time, stabilizing the circadian rhythm, and shortening the sleep latency.[46] One such study exposed patients with AD (and related dementias) to light at 350 to 400 lux for an average of 92 min of treatment (median 102 min) per 120 min treatment session for 4 weeks, and concluded that the mean percent time awake increased from 65% during baseline to 68% during treatment.[47] To further verify the effectiveness of LT in patients with sleep disorders, another study included 11 AD patients with sleep-wakefulness disorders. Those patients were exposed to 6000 to 8000 lux of morning light for 2 weeks for 2 h a day. This study found that, 2 weeks later, sleep efficiency was significantly improved and the amount of time spent sleeping during the day or spent awake at night was dramatically reduced.[48] The patients were followed to observe the long-term effects of LT, remarkable, sleep efficiency was still significantly better than the baseline 12 weeks after the last treatment. Additionally, light markedly decreased the sleep latency at 12 weeks [Table 2].[49]

Table 2 - Effect of light in AD patients.
First author, year, reference Participants Head-to-light distance Intervention Duration and frequency Assessment tools Outcome
Sonia Ancoli-Israel, 2010[59] 92 probable or possible Alzheimer's disease patients 1.0 m 2500 lux bright light or <300 lux red light 9:30 am to 11:30 am and 5:30 pm to 7:30 pm for 10 days The Actillume recorder Both morning and evening bright light resulted in more consolidated sleep at night
Sonia Ancoli-Israel, 2002[48] 77 dementia patients 1.0 m 2500 lux bright ligh tor <50 lux red light 9:30 am to 11:30 am and 5:30 pm to 7:30 pm for 10 days Scales and actillume recorder Increasing exposure to morning bright light delayed the acrophase of the activity rhythm and made the circadian rhythm more robust.
Constantine G Lyketsos, 1999[53] 15 AD patients 3 feet 10,000 lux bright light and dim, digital, low-frequency blinking light 1 h in the morning for 4 weeks and for an additional 4 weeks in the other condition Scales and sleep diaries Patients sleep more hours at night when administered morning BLT.
Glenna A. 2008[47] 70 AD patients 4 feet 2500 lux bright light or indoor light 09:30 am to 10:30 am or 3.30 pm to 4.30 pm Monday through Friday for 10 weeks Scales and actigraphy One hour of bright light, administered to subjects with AD either in the morning or afternoon, did not improve nighttime sleep or daytime wake compared to a control group of similar subjects.
Lisa L. Onega, 2016[56] 60 dementia patients 27 inches 10,000 lux bright light or 250 lux dim light 30 min twice a day (8:00 am to 12:00 pm, and 2:00 pm to 8:00 pm), five times a week for 8 weeks Scales and actigraphy Bright light exposure was associated with significant improvement in depression and agitation.
Barbara B, 1995[57] 6 dementia patients 1.0 m 2500 lux bright light 09:30 am to 11:30 am for two 10-day periods. Scales BLT can reduce agitation.
Alistair Burns, 2009[12] 48 dementia patients 10,000 lux bright light or 100 lux dim light 10:00 am –12:00 am for 2 weeks Scales and actigraphy BLT is a potential alternative to drug treatment in people with dementia who are agitated.
Andre Graf, 2001[55] 23 AD or VD patients 90 cm 3000 lux bright light or 100 lux dim light 2 h from 5:00 pm to 7:00 pm for 10 days Scales and body temperature Short-term evening BLT may exert beneficial effects on cognitive functioning in patients with dementia.
Rixt F, 2008[10] 189 dementia patients 1000 lux bright light or 300 lux dim light Between 10:00 am and 5:00 pm for 15 months Scales and actigraphy Light can improve some cognitive and noncognitive symptoms of dementia.
Ann Louise Barrick, 2010[58] 66 dementia patients 2000 lux bright light am bright light (7–11 am), pm bright light (4–8 pm), all day bright light (7 am –8 pm); or standard light for 3 weeks Actigraphy BLT does not appear promising as a treatment for agitation.
AD: Alzheimer disease; BLT: Bright light therapy; VD: Vascular dementia.

In contrast with those studies, several case-control studies have reported a total lack of effect of LT in some patients. Dowling et al[46] divided 70 AD patients into the experimental group and the control group. The experimental group was treated with 2500 lux (or more) in the morning (9:30–10:30 am) or in the afternoon (3:30–4:30 pm) every Monday through Friday for 10 weeks. The control group, however, received normal indoor light (150–200 lux). The outcomes of interest included sleep at night, awakening during the day, and rest-activity, and were determined by actigraphy. Disappointingly, their experiments showed the circadian rhythm and cognitive function improved remarkably in the questionable and mildly demented patients group, but not so in the moderately and severely demented patients. This could be because responses to light varied in AD patients undergoing different courses of treatment, and the severity of dementia also appeared to affect patients’ sensitivity to light.[56] Overall, previous studies have suggested mixed effects of LT on sleep disorders in AD patients, however, there appears to be a general trend toward a positive effect of LT on sleep. Since LT does not have significant adverse effects, larger studies with longer follow-up periods are warranted to verify whether the effects on sleep are significant and persist over time[57] [Table 2].

Cognitive impairment

Patients with AD experience various forms of cognitive impairment including impaired memory, language, visual-spatial skills, task execution, comprehension, and judgment, even during symptomatic treatment.[51] Defects in two or more of the above cognitive domains may seriously affect the individual's daily or social abilities.[58] The positive effect of light on cognition has been reported in many clinical studies. A balanced, placebo-controlled study of 23 AD patients which was randomly assigned to either evening bright light therapy (BLT) or dim light therapy showed that scores on the mini-mental state exam (MMSE), a test measuring cognitive function, were significantly improved after light treatment (P = 0.012).[54] A similar result was reported by another study, in which 27 patients received 3000 lux of light every morning for 4 weeks, resulting in a significant improvement in MMSE (7.8 ± 5.2 vs. 8.6 ± 6.3, P < 0.05).[56] However, some studies have suggested that LT does not improve cognitive function in patients with AD. For example, one study with 22 cases in the LT group and 26 cases in the control group were, respectively, given 10,000 lux and <100 lux of light from 10:00 am to 12:00 am, but the MMSE scale assessment results revealed no significant improvement in the cognitive level of the patients between two groups after light exposure.[12] Additionally, a double-blind randomized controlled trial divided 168 patients from nursing homes into two groups, who were exposed to either 1000 or 300 lux of daily light for between 15 months and 3.5 years. After treatment, the average score of MMSE in the LT group was reduced by 0.9 points relative to baseline. In contrast, the control group did not experience a significant change relative to the baseline.[10] However, taken altogether, the effects of light on cognitive function in patients with AD remains controversial. Of note, the MMSE scale used to assess the cognitive functions in most studies is a relatively insensitive screening test. Furthermore, repeated measurements with the same test may cause bias. Therefore, it is necessary to develop more comprehensive and objective methods for assessing the cognitive functions of AD patients [Table 2].

Mental disorders

AD patients often present with anxiety, depression, and other mental disorders. Studies on the impacts of light on associated mental disorders have shown that light may play a role in reducing agitation in dementia patients.[12] Similarly, Onega et al[52] demonstrated that bright environments significantly alleviate depression and agitation in patients with dementia. At the same time, LT is suggested to alleviate depression and restlessness in AD patients.[12,53] However, some studies have shown that bright environments may actually aggravate agitation in patients with dementia.[55] In short, the question of whether light alleviates emotional disorders remains a topic for further investigation [Table 2].

In conclusion, LT appears to generally have a positive effect on AD patients[51] and several clinical studies demonstrated that BLT can alleviate issues related to sleep disorders, depression, cognition, and agitation in AD patients. However, most studies are unable to exclude the influence of external light on the research results, and more data are required to provide unambiguous recommendation for or against the use of BLT in AD.

PD

PD, also known as paralysis agitans, is a common degenerative disease of the nervous system. It is characterized by tremor, bradykinesia, myotonia, and postural balance disorder. The incidence of PD is increasing annually alongside the progressively aging population of China. Currently, PD remains an incurable neurological disease. However, since it was developed 50 years ago, levodopa has been widely used as an effective treatment to relieve the motor symptoms associated with PD.[59] However, over time, patients experience diminishing the therapeutic effects of levodopa. After 5 years of treatment, fluctuation of motor symptoms and dyskinesia begin to reappear. Furthermore, dopaminergic drugs may have adverse reactions, such as daytime sleepiness and dopamine imbalance syndrome. The non-motor symptoms of PD are diverse and universal, but there are limited pharmaceutic options to address them. Increasing evidence has suggested that non-drug treatments for PD, such as BLT, physical exercise, and TMS, may be useful, cheap, and non-invasive treatment methods.[7] LT has an important impact on the circadian rhythm. First, the light activates the SCN via the hypothalamic bundle of the retina; second, light-sensing inhibits the secretion of MT; third, light promotes the connection between thalamus and cortex through indirectly activating sympathetic activity in the brainstem.[60] Currently, the primary treatments for PD are pharmaceutics, which can greatly alleviate the motor symptoms of PD.[61] However, there are very few treatments for the non-motor symptoms of PD, which sometimes precede the motor symptoms and also affect patients’ quality of life.[62] Several studies have shown that light alleviates some non-motor symptoms of PD patients, such as insomnia, depression, autonomic dysfunction, and fatigue.[63] However, publications on biological rhythms and PD are still rare.

Animal models

The majority of experimental data on animal models of PD come from John Mitrofanis laboratory in Australia. Specifically, for PD, the most used animal model is the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mouse model. MPTP is a neurotoxin that destroys dopaminergic cells in the substantia nigra to produce symptoms similar to PD and thus has been widely used in PD research. Details about the effects of red and NIr LT in different animal models are mentioned in Table 1. Below are the main experiments of interest, described in chronological order [Table 3].

Table 3 - Effect of light on animal models of PD.
First author, year, reference Subject Model PBM Parameters Effects
Victoria E Shaw, 2010[64] BALB/c albino Mice Acute MPTP Transcranial PBM, 1 cm above the head, 670 nm, 40 mw/cm2, 90 s, 10 cm2, 2 J/cm2 Dopaminergic cells in SNc↑
Cassandra Peoples, 2012[65] BALB/c male mice Chronic, Acute MPTP Transcranial PBM, 670 nm, 90 s, 0.5 J/cm2 Dopaminergic amacrine cells and TH+ cells in retina↑
Victoria E Shaw, 2012[66] BALB/c Mice Acute, chronic MPTP Transcranial PBM, 1–2 cm above the head, 670 nm, 90 s, 0.5 J/cm2 Fos+ cells in subthalamic nucleus and zona incerta ↓
Cassandra Peoples, 2012[67] BALB/c Mice Chronic MPTP Transcranial PBM, 1–2 cm above the head, 670 nm, 90 s, 5 J/cm2, 3–5 weeks TH+ cells in SNc↑
Melissa Vos, 2013[68] Dorsophila Pink 1 mutants Transcranial PBM, 808 nm, 25 mw/cm2, 2.5 J/cm2 Partially rescue the behavioral abnormalities and mitochondrial function of pink1 mutant
Cecile Moro, 2013[69] C57BL/6 pigmented mice Acute MPTP Transcranial PBM, 1–2 cm above the head, 670 nm, 90 s, 4 times, 2 J/cm2 TH+ cells ↑ Behavioral impairment ↓
Purushothuman S 2013[70] Mice K3 (tau transgenic mice) Loss of TH+ cells↓ stress biomarkers: increase of 4-HNE, 8-OHDG, AT-8↓
Cecile Moro 2014[71] BALB/c MiceSprague-Dawley rats Acute MPTP Implanted (lateral ventricles), 0.16 mw, 67 mw Dopaminergic cells ↑
Johnstone DM, 2014[19] Male BALB/c Mice MPTP Remote PBM (applied on the trunk and leg instead of head), 670 nm, 50 mw/cm2, 4 J/cm2 Damage of TH+ cells in SNc↓
Effects of direct transcranial application is better than remote PBM
Oueslati A, 2015[72] Sprague-Dawley female Rat AAV-based α-synuclein overexpression Transcranial PBM, 808 nm, 2.5–5 mw/cm2, 100 s, once daily for 28 days Behavioral damage↓
Loss of dopaminergic cells↓
Florian Reinhart, 2016[73] Male BALB/c Mice Acute MPTP Transcranial PBM, 670 nm, 90 s, twice daily, 1 J/cm2/d Whether PBM is simultaneously, before or after the MPTP injection, MPTP induced behavioral impairment↓ cell survival ↑
Darlot F, 2016[74] Macaque Monkey Subacute MPTP Implanted, 670 nm, 10 mw, 25 J/5 d, 35 J/7 d Clinical and behavioral impairment↓
Dopaminergic cells and their terminations in SN, TH+ cells in stratum↑
Nabil El Massri, 2016[75] Macaque Monkey Subacute MPTP Implanted (substantia nigra next to the midline of midbrain) 670 nm, 25/35 J, before injection: NIr delivery (5 s ON/60 s OFF); after injection: 24 h, 10 mw Astrogliosis in SNc and stratum ↓
Florian Reinhart, 2016[76] Wistar Rat 6-OHDA Implanted (Bergma coordinate (–5.6 mm, +2.9 mm, –8.5 mm) 20°), continuous or pulsed, 670 nm, 0.16 mw, twice daily for 23 days, 90 s per time, total dose of 634 mJ At the stronger power, apomorphine induced rotation↓
TH+ cells ↑
Nabil El Massri, 2017[77] Macaque MPTP Implanted (midbrain midline), 670 nm, 10 mw TH+ cells in stratum ↑
Monkey GDNF↑
Florian Reinhart, 2017[78] Male BALB/c Mice MPTP 670 nm and 810 nm (simultaneously or sequentially) 22 J, 2 days Motility ↑
TH+ cells in SNpc↑
Boaz Kim, 2018[20] Male C57BL/6 mice MPTP remote PBM before MPTP injection, 670 nm, 50 mw/cm2, 3 min Loss of dopaminergic cells↓
O’Brien, 2019[79] Sprague-Dawley Mice (Male) LPS Transcranial PBM, 670 nm, 50 mw/cm2, 88 s, twice daily for 6 days Loss of dopaminergic cells ↓
Varshika Ganeshan, 2019[21] BALB/c mice MPTP Remote PBM before MPTP injection, 670 nm, continuous wave, 4 J/cm2, 50 mw/cm2 Loss of TH+ cells in midbrain ↓
increase of FOS+ neurons in putamen and caudate nucleus↓
PBM: Photobiomodulation; SNc: Substantia Nigra compacta; SNpc: Substantia Nigra pars compacta; GDNF: Glial cell-derived Neuro trophic factor.

Patients

Motor symptoms

Motor symptoms, such as resting tremor, myotonia, bradykinesia, and postural balance disorder have significant impacts on the quality of life and prognosis of PD patients.[80] The Movement Disorder Society Unified PD Rating Scale, Part III (MDS-UPDRS III) is commonly used to assess motor symptoms. Motor symptoms are mainly alleviated through dopamine-based therapies. Interestingly, studies have shown that LT can reduce the need for dopamine drugs.[81] The effect of light on PD motor symptoms is less investigated and is a topic requiring further exploration. In one study, some of the PD patients were treated with 1 h of 10,000 lux of light after waking up (no later than 9 o’clock) for 30 min daily for 10 days, and the patients of the control group were exposed to <2500 lux of light. This study found that BLT led to significant alleviation of tremor, UPDRS III and IV, and depression in the active treatment group.[8] However, since the effect of environmental light may not have been adequately controlled, this may be a biased result. Another study found that 14 days of LT led to significant improvements in the total UPDRS score and the UPDRS parts I, II, and III scores [Table 4].[82] Importantly, the mechanism of the effect of light on improving motor symptoms in PD patients lacks theoretical support and requires further clinical and mechanistic verification.

Table 4 - Effect of light in PD patients.
First author, year, reference Participants Head-to-light distance Intervention Duration and frequency Assessment tools Outcome
Sebastian Paus, 2007[8] 36 PD patients 20 cm in the active treatment, and 100 cm in the placebo group 7500 lux in the active treatment group and 950 lux in the placebo group 15 days in the morning, 30 min daily for 1 week Scales BLT led to significant improvement of tremor, UPDRS I, II, and IV, and depression in the active treatment group but not in the placebo group.
Aleksandar Videnovic, 2017[83] 31 PD patients 86.4 cm BLT (±10,000 lux) or dim red light (<300 lux). In the morning (9–11 am) and in the afternoon (5–7 pm) daily for 2 weeks. Scales, Actigraphy Light therapy was well tolerated and maybe a feasible intervention for improving the sleep-wake cycles in patients with PD.
Jessica K, 2018[92] 140 PD patients 0.8–1.0 m 3000 to 4000 lux for one to four hours Daily bright light exposure for 2–5 years Scales and diaries The application of LT before retiring can improve the quality of sleep and reduce the incidence of nocturnal movement.
Gregory L. Willis, 2018[95] 30 PD patients 0.8–1.0 m 3000 lux polychromatic light, red light and discontinued polychromatic light 11 am to 1 pm daily for 2 weeks Scales Continued exposure to polychromatic light over a 2-week period results in incremental improvement in motor and psychiatric parameters associated with PD.
Sonja Rutten, 2019[6] 83 patients with PD and MDD 30–40 cm BLT (±10,000 lux) or a control light (±200 lux) Daily for 30 min in the morning and evening for 3 consecutive months Cortisol, scales and diary BLT was not more effective in reducing depressive symptoms than a control light. Mood and subjective sleep improved in both groups. BLT was more effective in improving subjective sleep quality than control light.
PD: Parkinson disease; BLT: Bright light therapy; UPDRS: Unified PD rating scale; MDD: Major depressive disorder.

Non-motor symptoms

Recently, there has been increasing research focus on the non-motor symptoms of PD, which include depression, sleep disorders, constipation, salivation, dysphagia, hyperhidrosis, weight loss, orthostatic hypotension, frequent micturition, sexual dysfunction, and others.[85] These non-motor symptoms have negative impacts on quality of life throughout the course of the disease and thus urgently require the development of safe and effective therapeutic options.[59,61,62]

Sleep disorders are a common non-motor symptom of PD and mainly manifest as daytime sleepiness, insomnia, rapid eye movement behavior disorder, restless legs syndrome, and sleep-disordered breathing.[86] Notably, sleep disturbances affect 40% to 98% of PD patients in the world.[87–89] In China, the prevalence of sleep disturbance among PD patients ranges from 47.66% to 89.10%.[90] Sleep disorders can reduce the quality of life and impair daytime function.

Interestingly, clinical studies have confirmed the safety and effectiveness of light in improving insomnia and daytime sleepiness of PD patients. Indeed, a study of patients with PD with sleep disorders found that stronger light had a more significant treatment effect. Videnovic et al[82] randomly assigned patients with daytime sleepiness into two sex- and age-matched groups, who received 10,000 and 200 lux of irradiation for 2 weeks. The Epworth sleepiness scale was used to evaluate outcomes and revealed that daytime sleepiness symptoms were significantly alleviated in the experimental group relative to the control group. Long-term follow-up studies of PD patients with insomnia have indicated that 2 to 5 years of light treatment can alleviate insomnia symptoms.[91] Some studies have also confirmed that LT can alleviate rapid-eye-movement sleep behavior disorder, suggesting that symptoms were gradually alleviated from the third month through the 60th month of treatment, with better effects between the 6th and 11th months than the first 2 months of treatment.[91]

Strikingly, up to 35% of patients with PD have clinically relevant symptoms of depression.[92] Several studies have compared the changes of depression symptoms in PD patients, as evaluated by the Hamilton Depression Scale (HAMD/HDRS) and other scales, before and after LT. One such study recently gave patients with PD and depression either 10,000 or 200 lux of light separately for 3 months and followed up at the first, second, and sixth months after treatment. Disappointingly, they found that there was no difference in depressive symptoms between the groups. This study suggests that LT does not significantly alleviate the depressive symptoms of PD patients.[6] In contrast, Sonja Rutten et al[9] used bright light (±10,000 lux) or a control light (±200 lux) daily for 30 min in the morning and evening for at least 1 week in 83 patients and found that BLT was more effective in improving subjective sleep quality than control light. In terms of cognitive impairment in PD patients, the study has suggested that BLT may improve the cognitive function of PD patients, mainly through the MMSE scale.[8] However, this result may be caused by repeated measurements. We should adopt more precise cognitive function assessment methods to avoid the change of scores caused by repeated measurement. In terms of autonomic nerve function, fatigue, and other non-motor symptoms of PD, more researches are needed.

In summary, the light may alleviate motor symptoms and some non-motor symptoms in PD patients, such as sleep disorders, but these results require further confirmation [Table 4].

LT in Other ND

Little research has been conducted on the therapeutic use of light in other types of ND, and most such studies are still at preclinical, experimental studies in model mice. HD is an ND that lacks a specific treatment.[93] It has been shown that, after exposure to blue light for 6 h a day for 3 months, the activity rhythms of both bacterial artificial chromosome-mediated transgenic mouse model and Q175 mice were alleviated, but no significant improvement in sleep behavior was observed. Compared with the untreated control group, the motor function of the treated mice of both genotypes was alleviated. Given the changes in the expression of some HD-related markers in the striatum and cortex of the treated mice, the authors speculated that light may alleviate the motor symptoms of the HD model mice. This makes sense in the context of other research suggesting that stimulation of the circadian system can delay the progression of HD.[94]

Other studies have explored the effect of light treatment in mice models with familial amyotrophic lateral sclerosis, but there was no significant difference in the survival rate or exercise ability of mice between groups, suggesting that LT may not be helpful for familial amyotrophic lateral sclerosis disease.[95]

There is a lack of animal experiments and clinical trials on the use of light in treating other types of ND at present, but we believe that the broad safety and potential efficacy of light should facilitate more research on the use of LT for other NDs.

Although the tolerance of LT is generally good, about 45% of patients may have mild adverse reactions during the early stages of treatment, including headache, visual fatigue, blurred vision, eye irritation, or elevated blood pressure. Inappropriate LT may also cause insomnia. Rare adverse reactions, such as mania, mood instability, and attempted suicide, may be due to light-induced alertness and should be carefully assessed. However, this assumption is not very certain at present, and it is not clear whether there is a true causal link between LT and aggravated symptoms in some people. Adverse reactions can be reduced by reducing exposure time.[6,11,12,46–48,51,54,82,96,97]

Future Perspectives

LT as a treatment for NDs presents the advantages of being low cost and having relatively minor side effects. The rapid advancements in research on LT as a treatment for ND in recent years have provided a mechanistic basis for its clinical effects by acting on the circadian rhythm, but there have been conflicting reports of efficacy across trials, potentially due to varying light intensities, light equipment, and treatment times across studies.

Studies have shown that the body reaches its lowest temperature at approximately 4:00 am; after which light exposure will adjust the biological clock to an earlier schedule, according to the light phase curve.[98] Similarly, light exposure before arriving at the lowest body temperature has the opposite effect of setting the biological clock to a later time. The effects of light on the biological clock are strongest near the time at which the human body reaches its lowest temperature. The further light exposure occurs from this time point, the smaller the effect. This implies that LT should be started as early in the morning as possible. In addition, some studies have classified the “time type” of the patients using the morning-night type scale, and determined light time accordingly.[6,99] Between 1000 and 10,000 lux of visible light is often applied to ND patients for times ranging from 1 week to several years and for daily treatment periods ranging from 30 min to 24 h a day.[3–6,8–12,46–58,82,84,91] The light is typically 20 cm to 1 m away from the human eyes. However, the application of light treatment in ND is still very much at the research stage, and there are no unified treatment guidelines outlining the time, intensity, or other parameters required for successful LT. With increasing research, such a guide will be crucial to standardize LT in the future.

Thus LT still has its limitations. It is inherently difficult to study light quantitatively because both the time of year and natural exposure to the sun have important effects on circadian rhythm.[12] To quantify the impact of outdoor light exposure on the results of the study, some scholars have suggested that different seasons should be equally distributed between the treatment and control groups in future research,[55,83] thereby mitigating the effects of the season. Moreover, the baseline light level, clear light intensity, color temperature, wavelength, duration of treatment, and daily treatment time should be taken into account and clearly reported.[82] The influence of external light can also be eliminated by calculating the light using quantitative instruments. It is possible that, in the next few years, light-related research may be developed into a safe and effective treatment for ND. Last but not least, because of the different pathogenesis of the ND, it is difficult to explain the effectiveness of LT in different ND, which needs more mechanism research.

LT represents a new, non-pharmaceutic, well-tolerated therapy with global applicability. The improvement of ND symptoms observed in some studies of LT is encouraging. However, in the future, large, randomized, and controlled studies are needed to better clarify the potential mechanisms through which LT effects ND and to determine the optimal frequency, duration, intensity, and other parameters for safe and effective LT.

Funding

This work was supported by the National Natural Science Foundation of China (Nos. 81908217, 81801253 and 91649114), the Natural Science foundation of Jiangsu Higher Education Institutions of China (No. 19KJB180007), Jiangsu Provincial Social Development Projects (Nos. BE2018658, BE2017653), Jiangsu Provincial Medical Key Discipline Project (No. ZDXKB2016022), Jiangsu Province Postgraduate Training Innovation Project (No. KYCX18_2545), Suzhou Clinical Research Center of Neurological Disease (No. Szzx201503). The work was also supported by grants from the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Conflicts of interest

None.

References

1. Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010; 25:2395–2404. doi: 10.1002/mds.23291.
2. Latorre A, Rocchi L, Berardelli A, Bhatia KP, Rothwell JC. The interindividual variability of transcranial magnetic stimulation effects: Implications for diagnostic use in movement disorders. Mov Disord 2019; 34:936–949. doi: 10.1002/mds.27736.
3. Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, et al. Repetitive transcranial magnetic stimulation for functional tremor: a randomized, double-blind, controlled study. Mov Disord 2019; 34:1210–1219. doi: 10.1002/mds.27727.
4. Latorre A, Rocchi L, Berardelli A, Bhatia KP, Rothwell JC. The use of transcranial magnetic stimulation as a treatment for movement disorders: a critical review. Mov Disord 2019; 34:769–782. doi: 10.1002/mds.27705.
5. Buard I, Sciacca DM, Martin CS, Rogers S, Silau SH, Greher MR, et al. Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease. Mov Disord 2018; 33:489–491. doi: 10.1002/mds.27246.
6. Rutten S, Vriend C, Smit JH, Berendse HW, van Someren EJW, Hoogendoorn AW, et al. Bright light therapy for depression in Parkinson disease: a randomized controlled trial. Neurology 2019; 92:e1145–e1156. doi: 10.1212/WNL.0000000000007090.
7. Fifel K, Videnovic A. Chronotherapies for Parkinson's disease. Prog Neurobiol 2019; 174:16–27. doi: 10.1016/j.pneurobio.2019.01.002.
8. Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: a pilot study. Mov Disord 2007; 22:1495–1498. doi: 10.1002/mds.21542.
9. Rutten S, Vriend C, Smit JH, Berendse HW, Hoogendoorn AW, van den Heuvel OA. A double-blind randomized controlled trial to assess the effect of bright light therapy on depression in patients with Parkinson's disease. BMC Psychiatry 2016; 16:355doi: 10.1186/s12888-016-1050-z.
10. Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008; 299:2642–2655. doi: 10.1001/jama.299.22.2642.
11. Van Someren EJ, Kessler A, Mirmiran M, Swaab DF. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry 1997; 41:955–963. doi: 10.1016/S0006-3223 (97)89928-3.
12. Burns A, Allen H, Tomenson B, Duignan D, Byrne J. Bright light therapy for agitation in dementia: a randomized controlled trial. Int Psychogeriatr 2009; 21:711–721. doi: 10.1017/S1041610209008886.
13. Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 2014; 71:463–469. doi: 10.1001/jamaneurol.2013.6239.
14. Youngstedt SD, Kline CE, Elliott JA, Zielinski MR, Devlin TM, Moore TA. Circadian phase-shifting effects of bright light, exercise, and bright light + exercise. J Circadian Rhythms 2016; 14:2doi: 10.5334/jcr.137.
15. Yoshizaki T, Tada Y, Hida A, Sunami A, Yokoyama Y, Yasuda J, et al. Effects of feeding schedule changes on the circadian phase of the cardiac autonomic nervous system and serum lipid levels. Eur J Appl Physiol 2013; 113:2603–2611. doi: 10.1007/s00421-013-2702-z.
16. Zhang P, Moye LS, Southey BR, Dripps L, Sweedler JV, Pradhan A, et al. Opioid-induced hyperalgesia is associated with dysregulation of circadian rhythm and adaptive immune pathways in the mouse trigeminal ganglia and nucleus accumbens. Mol Neurobiol 2019; 56:7929–7949. doi: 10.1007/s12035-019-01650-5.
17. Weissová K, Škrabalová J, Skálová K, Cervena K, Bendova Z, Miletinova E, et al. Circadian rhythms of melatonin and peripheral clock gene expression in idiopathic REM sleep behavior disorder. Sleep Med 2018; 52:1–6. doi: 10.1016/j.sleep.2018.07.019.
18. Stein RM, Kang HJ, McCorvy JD, Glatfelter GC, Jones AJ, Che T, et al. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature 2020; 579:609–614. doi: 10.1038/s41586-020-2027-0.
19. Johnstone DM, el Massri N, Moro C, Spana S, Wang XS, Torres N, et al. Indirect application of near infrared light induces neuroprotection in a mouse model of parkinsonism – an abscopal neuroprotective effect. Neuroscience 2014; 274:93–101. doi: 10.1016/j.neuroscience.2014.05.023.
20. Kim B, Mitrofanis J, Stone J, Johnstone DM. Remote tissue conditioning is neuroprotective against MPTP insult in mice. IBRO Rep 2018; 4:14–17. doi: 10.1016/j.ibror.2018.01.001.
21. Ganeshan V, Skladnev NV, Kim JY, Mitrofanis J, Stone J, Johnstone DM. Pre-conditioning with remote photobiomodulation modulates the brain transcriptome and protects against MPTP insult in mice. Neuroscience 2019; 400:85–97. doi: 10.1016/j.neuroscience.2018.12.050.
22. Ball KA, Castello PR, Poyton RO. Low intensity light stimulates nitrite-dependent nitric oxide synthesis but not oxygen consumption by cytochrome c oxidase: Implications for phototherapy. J Photochem Photobiol B 2011; 102:182–191. doi: 10.1016/j.jphotobiol.2010.12.002.
23. Lane N. Cell biology: power games. Nature 2006; 443:901–903. doi: 10.1038/443901a.
24. Karu TI, Kolyakov SF. Exact action spectra for cellular responses relevant to phototherapy. Photomed Laser Surg 2005; 23:355–361. doi: 10.1089/pho.2005.23.355.
25. Santana-Blank L, Rodríguez-Santana E, Santana-Rodríguez K. Theoretic, experimental, clinical bases of the water oscillator hypothesis in near-infrared photobiomodulation. Photomed Laser Surg 2010; 28: (Suppl 1): S41–S52. doi: 10.1089/pho.2009.2647.
26. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng 2012; 40:516–533. doi: 10.1007/s10439-011-0454-7.
27. Wu S, Zhou F, Wei Y, Chen WR, Chen Q, Xing D. Cancer phototherapy via selective photoinactivation of respiratory chain oxidase to trigger a fatal superoxide anion burst. Antioxid Redox Signal 2014; 20:733–746. doi: 10.1089/ars.2013.5229.
28. Taylor RC, Berendzen KM, Dillin A. Systemic stress signalling: understanding the cell non-autonomous control of proteostasis. Nat Rev Mol Cell Biol 2014; 15:211–217. doi: 10.1038/nrm3752.
29. Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR. Photobiomodulation of human adipose-derived stem cells using 810 nm and 980 nm lasers operates via different mechanisms of action. Biochim Biophys Acta Gen Subj 2017; 1861:441–449. doi: 10.1016/j.bbagen.2016.10.008.
30. Barrett DW, Gonzalez-Lima F. Transcranial infrared laser stimulation produces beneficial cognitive and emotional effects in humans. Neuroscience 2013; 230:13–23. doi: 10.1016/j.neuroscience.2012.11.016.
31. Dougal G, Lee SY. Evaluation of the efficacy of low-level light therapy using 1072 nm infrared light for the treatment of herpes simplex labialis. Clin Exp Dermatol 2013; 38:713–718. doi: 10.1111/ced.12069.
32. Qaseem A, Snow V, Cross JT, Forciea MA, Hopkins R, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148:370–378. doi: 10.7326/0003-4819-148-5-200803040-00008.
33. Bubu OM, Andrade AG, Umasabor-Bubu OQ, Hogan MM, Turner AD, de Leon MJ, et al. Obstructive sleep apnea, cognition and Alzheimer's disease: a systematic review integrating three decades of multidisciplinary research. Sleep Med Rev 2020; 50:101250doi: 10.1016/j.smrv.2019.101250.
34. De Taboada L, Yu J, El-Amouri S, Gattoni-Celli S, Richieri S, McCarthy T, et al. Transcranial laser therapy attenuates amyloid-β peptide neuropathology in amyloid-β protein precursor transgenic mice. J Alzheimers Dis 2011; 23:521–535. doi: 10.3233/JAD-2010-100894.
35. Rojas JC, Bruchey AK, Gonzalez-Lima F. Low-level light therapy improves cortical metabolic capacity and memory retention. J Alzheimers Dis 2012; 32:741–752. doi: 10.3233/JAD-2012-120817.
    36. Meng C, He Z, Xing D. Low-level laser therapy rescues dendrite atrophy via upregulating BDNF expression: implications for Alzheimer's disease. J Neurosci 2013; 33:13505–13517. doi: 10.1523/JNEUROSCI.0918-13.2013.
    37. Purushothuman S, Johnstone DM, Nandasena C, Mitrofanis J, Stone J. Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex – evidence from two transgenic mouse models. Alzheimers Res Ther 2014; 6:2doi: 10.1186/alzrt232.
    38. Farfara D, Tuby H, Trudler D, Doron-Mandel E, Maltz L, Vassar RJ, et al. Low-level laser therapy ameliorates disease progression in a mouse model of Alzheimer's disease. J Mol Neurosci 2015; 55:430–436. doi: 10.1007/s12031-014-0354-z.
    39. Purushothuman S, Johnstone DM, Nandasena C, van Eersel J, Ittner LM, Mitrofanis J, et al. Near infrared light mitigates cerebellar pathology in transgenic mouse models of dementia. Neurosci Lett 2015; 591:155–159. doi: 10.1016/j.neulet.2015.02.037.
    40. Cho GM, Lee SY, Park JH, Kim MJ, Park KJ, Choi BT, et al. Photobiomodulation using a low-level light-emitting diode improves cognitive dysfunction in the 5XFAD mouse model of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2020; 75:631–639. doi: 10.1093/gerona/gly240.
      41. Blivet G, Meunier J, Roman FJ, Touchon J. Neuroprotective effect of a new photobiomodulation technique against Aβ25–35 peptide–induced toxicity in mice: novel hypothesis for therapeutic approach of Alzheimer's disease suggested. Alzheimer's Dement Transl Res Clin Intervent 2018; 4:54–63. doi: 10.1016/j.trci.2017.12.003.
        42. Zinchenko E, Navolokin N, Shirokov A, Khlebtsov B, Dubrovsky A, Saranceva E, et al. Pilot study of transcranial photobiomodulation of lymphatic clearance of beta-amyloid from the mouse brain: breakthrough strategies for non-pharmacologic therapy of Alzheimer's disease. Biomed Opt Express 2019; 10:4003–4017. doi: 10.1364/BOE.10.004003.
        43. Wang M, Cao J, Amakye WK, Gong C, Li Q, Ren J. Mid infrared light treatment attenuates cognitive decline and alters the gut microbiota community in APP/PS1 mouse model. Biochem Biophys Res Commun 2020; 523:60–65. doi: 10.1016/j.bbrc.2019.12.015.
        44. Yue X, Mei Y, Zhang Y, Tong Z, Cui D, Yang J, et al. New insight into Alzheimer's disease: light reverses Aβ-obstructed interstitial fluid flow and ameliorates memory decline in APP/PS1 mice. Alzheimer's Dement 2019; 5:671–684. doi: 10.1016/j.trci.2019.09.007.
        45. Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology - a bidirectional relationship. Nat Rev Neurol 2014; 10:115–119. doi: 10.1038/nrneurol.2013.269.
        46. Dowling GA, Mastick J, Hubbard EM, Luxenberg JS, Burr RL. Effect of timed bright light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. Int J Geriatr Psychiatry 2005; 20:738–743. doi: 10.1002/gps.1352.
        47. Ancoli-Israel S, Martin JL, Kripke DF, Marler M, Klauber MR. Effect of light treatment on sleep and circadian rhythms in demented nursing home patients. J Am Geriatr Soc 2002; 50:282–289. doi: 10.1046/j.1532-5415.2002.50060.x.
        48. Fetveit A, Bjorvatn B. Bright-light treatment reduces actigraphic-measured daytime sleep in nursing home patients with dementia: a pilot study. Am J Geriatr Psychiatry 2005; 13:420–423. doi: 10.1176/appi.ajgp.13.5.420.
        49. Fetveit A, Bjorvatn B. The effects of bright-light therapy on actigraphical measured sleep last for several weeks post-treatment. A study in a nursing home population. J Sleep Res 2004; 13:153–158. doi: 10.1111/j.1365-2869.2004.00396.x.
        50. Ancoli-Israel S, Gehrman P, Martin JL, Shochat T, Marler M, Corey-Bloom J, et al. Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients. Behav Sleep Med 2003; 1:22–36. doi: 10.1207/S15402010BSM0101_4.
        51. Lyketsos CG, Lindell Veiel L, Baker A, Steele C. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. Int J Geriatr Psychiatry 1999; 14:520–525. doi: 10.1002/(sici)1099-1166(199907)14:7<520:aid-gps983>3.3.co;2-d.
        52. Onega LL, Pierce TW, Epperly L. Effect of bright light exposure on depression and agitation in older adults with dementia. Issues Ment Health Nurs 2016; 37:660–667. doi: 10.1080/01612840.2016.1183736.
        53. Lovell BB, Ancoli-Israel S, Gevirtz R. Effect of bright light treatment on agitated behavior in institutionalized elderly subjects. Psychiatry Res 1995; 57:7–12. doi: 10.1016/0165-1781(95)02550-g.
        54. Graf A, Wallner C, Schubert V, Willeit M, Wlk W, Fischer P, et al. The effects of light therapy on mini-mental state examination scores in demented patients. Biol Psychiatry 2001; 50:725–727. doi: 10.1016/s0006-3223(01)01178-7.
        55. Barrick AL, Sloane PD, Williams CS, Mitchell CM, Connell BR, Wood W, et al. Impact of ambient bright light on agitation in dementia. Int J Geriatr Psychiatry 2010; 25:1013–1021. doi: 10.1002/gps.2453.
        56. Yamadera H, Ito T, Ito R, Endo S. Effects of bright light on cognitive and sleep-wake (circadian) rhythm disturbances in Alzheimer-type dementia. Psychiatry Clin Neurosci 2000; 54:352–353. doi: 10.1272/jnms.66.229.
        57. Mitolo M, Tonon C, La Morgia C, Testa C, Carelli V, Lodi R. Effects of light treatment on sleep, cognition, mood, and behavior in Alzheimer's disease: a systematic review. Dement Geriatr Cogn Disord 2018; 46:371–384. doi: 10.1159/000494921.
        58. Sung-Wan K, Xiaoling X. The influence of cognitive impairment on health behaviors among older adults. Am J Health Behav 2020; 44:159–168. doi: 10.5993/AJHB.44.2.4.
        59. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers 2017; 3:17013doi: 10.1038/nrdp.2017.13.
        60. Czeisler CA, Allan JS, Strogatz SH, Ronda JM, Sanchez R, Rios CD, et al. Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science 1986; 233:667–671. doi: 10.1126/science.3726555.
        61. Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 2015; 30:4–18. doi: 10.1002/mds.26102.
        62. Li G, Ma J, Cui S, He Y, Xiao Q, Liu J, et al. Parkinson's disease in China: a forty-year growing track of bedside work. Transl Neurodegener 2019; 8:22doi: 10.1186/s40035-019-0162-z.
        63. Li Z, Tian T. Light therapy promoting dopamine release by stimulating retina in Parkinson disease. JAMA Neurol 2017; 74:1267–1268. doi: 10.1001/jamaneurol.2017.1906.
        64. Shaw VE, Spana S, Ashkan K, Benabid AL, Stone J, Baker GE, et al. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J Comp Neurol 2010; 518:25–40. doi: 10.1002/cne.22207.
          65. Peoples C, Shaw VE, Stone J, Jeffery G, Baker GE, Mitrofanis J. Survival of dopaminergic amacrine cells after near-infrared light treatment in MPTP-treated mice. ISRN Neurol 2012; 2012:850150doi: 10.5402/2012/850150.
            66. Shaw VE, Peoples C, Spana S, Ashkan K, Benabid AL, Stone J, et al. Patterns of cell activity in the subthalamic region associated with the neuroprotective action of near-infrared light treatment in MPTP-treated mice. Parkinsons Dis 2012; 2012:296875doi: 10.1155/2012/296875.
              67. Peoples C, Spana S, Ashkan K, Benabid AL, Stone J, Baker GE, et al. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease. Parkinsonism Relat Disord 2012; 18:469–476. doi: 10.1016/j.parkreldis.2012.01.005.
                68. Vos M, Lovisa B, Geens A, Morais VA, Wagnieres G, van den Bergh H, et al. Near-infrared 808 nm light boosts complex IV-dependent respiration and rescues a Parkinson-related pink1 model. PLoS One 2013; 8:e78562doi: 10.1371/journal.pone.0078562.
                  69. Moro C, Torres N, El Massri N, Ratel D, Johnstone DM, Stone J, et al. Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains. BMC Neurosci 2013; 14:40doi: 10.1186/1471-2202-14-40.
                    70. Purushothuman S, Nandasena C, Johnstone DM, Stone J, Mitrofanis J. The impact of near-infrared light on dopaminergic cell survival in a transgenic mouse model of Parkinsonism. Brain Res 2013; 1535:61–70. doi: 10.1016/j.brainres.2013.08.047.
                      71. Moro C, Massri NE, Torres N, Ratel D, De Jaeger X, Chabrol C, et al. Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. J Neurosurg 2014; 120:670–683. doi: 10.3171/2013.9.JNS13423.
                        72. Oueslati A, Lovisa B, Perrin J, Wagnieres G, van den Bergh H, Tardy Y, et al. Photobiomodulation suppresses alpha-synuclein-induced toxicity in an AAV-based rat genetic model of Parkinson's disease. PLoS One 2015; 10:e0140880doi: 10.1371/journal.pone.0140880.
                          73. Reinhart F, El Massri N, Johnstone DM, Stone J, Mitrofanis J, Benabid AL, et al. Near-infrared light (670 nm) reduces MPTP-induced Parkinsonism within a broad therapeutic time window. Exp Brain Res 2016; 234:1787–1794. doi: 10.1007/s00221-016-4578-8.
                            74. Darlot F, Moro C, El Massri N, Chabrol C, Johnstone DM, Reinhart F, et al. Near-infrared light is neuroprotective in a monkey model of Parkinson disease. Ann Neurol 2016; 79:59–75. doi: 10.1002/ana.24542.
                              75. El Massri N, Moro C, Torres N, Darlot F, Agay D, Chabrol C, et al. Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys. Exp Brain Res 2016; 234:3225–3232. doi: 10.1007/s00221-016-4720-7.
                                76. Reinhart F, Massri NE, Chabrol C, Cretallaz C, Johnstone DM, Torres N, et al. Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival. J Neurosurg 2016; 124:1829–1841. doi: 10.3171/2015.5.JNS15735.
                                  77. El Massri N, Lemgruber AP, Rowe IJ, Moro C, Torres N, Reinhart F, et al. Photobiomodulation-induced changes in a monkey model of Parkinson's disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum. Exp Brain Res 2017; 235:1861–1874. doi: 10.1007/s00221-017-4937-0.
                                    78. Reinhart F, Massri NE, Torres N, Chabrol C, Molet J, Johnstone DM, et al. The behavioural and neuroprotective outcomes when 670 nm and 810 nm near infrared light are applied together in MPTP-treated mice. Neurosci Res 2017; 117:42–47. doi: 10.1016/j.neures.2016.11.006.
                                      79. O’Brien JA, Austin PJ. Effect of photobiomodulation in rescuing lipopolysaccharide-induced dopaminergic cell loss in the male Sprague-Dawley rat. Biomolecules 2019; 381:1–20. doi: 10.3390/biom9080381.
                                        80. Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord 2018; 33:1248–1266. doi: 10.1002/mds.27372.
                                        81. Videnovic A, Klerman EB, Zee PC. Light therapy promoting dopamine release by stimulating retina in Parkinson disease – reply. JAMA Neurol 2017; 74:1268–1269. doi: 10.1001/jamaneurol.2017.1909.
                                        82. Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: a randomized clinical trial. JAMA Neurol 2017; 74:411–418. doi: 10.1001/jamaneurol.2016.5192.
                                        83. Sloane PD, Williams CS, Mitchell CM, Preisser JS, Wood W, Barrick AL, et al. High-intensity environmental light in dementia: effect on sleep and activity. J Am Geriatr Soc 2007; 55:1524–1533. doi: 10.1111/j.1532-5415.2007.01358.x.
                                        84. Willis GL, Boda J, Freelance CB. Polychromatic light exposure as a therapeutic in the treatment and management of Parkinson's disease: a controlled exploratory trial. Front Neurol 2018; 9:741doi: 10.3389/fneur.2018.00741.
                                        85. Yu RL, Wu RM, Chan AY, Mok V, Wu YR, Tilley BC, et al. Cross-cultural differences of the non-motor symptoms studied by the traditional Chinese version of the International Parkinson and Movement Disorder Society–Unified Parkinson's Disease Rating Scale. Mov Disord Clin Pract 2017; 4:68–77. doi: 10.1002/mdc3.12349.
                                        86. Liu CF, Wang T, Zhan SQ, Geng DQ, Wang J, Liu J, et al. Management recommendations on sleep disturbance of patients with Parkinson's disease. Chin Med J 2018; 131:2976–2985. doi: 10.4103/0366-6999.247210.
                                        87. Amara AW, Chahine LM, Videnovic A. Treatment of sleep dysfunction in Parkinson's disease. Curr Treat Options Neurol 2017; 19:26doi: 10.1007/s11940-017-0461-6.
                                        88. Albers JA, Chand P, Anch AM. Multifactorial sleep disturbance in Parkinson's disease. Sleep Med 2017; 35:41–48. doi: 10.1016/j.sleep.2017.03.026.
                                        89. Selvaraj VK, Keshavamurthy B. Sleep dysfunction in Parkinson's disease. J Clin Diagn Res 2016; 10:OC09–OC12. doi: 10.7860/JCDR/2016/16446.7208.
                                        90. Zhang H, Gu Z, An J, Wang C, Chan P. Non-motor symptoms in treated and untreated Chinese patients with early Parkinson's disease. Tohoku J Exp Med 2014; 232:129–136. doi: 10.1620/tjem.232.129.
                                        91. Martino JK, Freelance CB, Willis GL. The effect of light exposure on insomnia and nocturnal movement in Parkinson's disease: an open label, retrospective, longitudinal study. Sleep Med 2018; 44:24–31. doi: 10.1016/j.sleep.2018.01.001.
                                        92. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23:183–189. doi: 10.1002/mds.21803.
                                        93. Aguiar S, van der Gaag B, Cortese FAB. RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA. Transl Neurodegener 2017; 6:30doi: 10.1186/s40035-017-0101-9.
                                        94. Wang H, Whittaker DS, Truong D, Mulji AK, Ghiani CA, Loh DH, et al. Blue light therapy improves circadian dysfunction as well as motor symptoms in two mouse models of Huntington's disease. Neurobiol Sleep Circadian Rhythms 2017; 2:39–52. doi: 10.1016/j.nbscr.2016.12.002.
                                        95. Moges H, Vasconcelos OM, Campbell WW, Borke RC, McCoy JA, Kaczmarczyk L, et al. Light therapy and supplementary Riboflavin in the SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis (FALS). Lasers Surg Med 2009; 41:52–59. doi: 10.1002/lsm.20732.
                                        96. Blagonravov ML, Bryk AA, Goryachev VA, Medvedeva EV, Demurov EA, Korshunova AY. Bright light therapy increases blood pressure and changes the structure of circadian rhythm of melatonin secretion in spontaneously hypertensive rats. Bull Exp Biol Med 2019; 168:214–218. doi: 10.1007/s10517-019-04677-9.
                                        97. Lee D, Shin WC. Forced entrainment by using light therapy, modafinil and melatonin in a sighted patient with non-24-hour sleep-wake disorder. Sleep Med 2015; 16:305–307. doi: 10.1016/j.sleep.2014.09.020.
                                        98. Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol 2019; 18:307–318. doi: 10.1016/S1474-4422(18)30461-7.
                                        99. Roenneberg T, Keller LK, Fischer D, Matera JL, Vetter C, Winnebeck EC. Human activity and rest in situ. Methods Enzymol 2015; 552:257–283. doi: 10.1016/bs.mie.2014.11.028.
                                        100. Lu Y, Wang R, Dong Y, Tucker D, Zhao N, Ahmed ME, et al. Low-level laser therapy for beta amyloid toxicity in rat hippocampus. Neurobiol Aging 2017; 49:165–182. doi: 10.1016/j.neurobiolaging.2016.10.003.
                                          Keywords:

                                          Neurodegenerative diseases; Light therapy; Circadian rhythm

                                          Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.